Evidence map›Paper›PMID 25105592›Full record

ArticlePloS one2014

Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways.

Aishwarya G Jacob, Ravi K Singh, Daniel F Comiskey, Matthew F Rouhier, Fuad Mohammad, Thomas W Bebee, Dawn S Chandler

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Oncogenic Functions of Alternatively SplicedInternational journal of molecular sciences · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. SRSF2 Regulation ofMolecular cancer research : MCR · 2020
    Article
  9. MDM2-C Functions as an E3 Ubiquitin Ligase.Cancer management and research · 2020
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Aishwarya G JacobFrom the Center for Childhood Cancer at the Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America; The Department of Pediatrics, and Molecular, Cellular and Developmental Biology (MCDB) program, The Ohio State University, Columbus, Ohio, United States of America; Center for RNA Biology, Wexner Medical Center, The Ohio State University, Columbus, Ohio, United States of America.
Ravi K SinghFrom the Center for Childhood Cancer at the Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America; The Department of Pediatrics, and Molecular, Cellular and Developmental Biology (MCDB) program, The Ohio State University, Columbus, Ohio, United States of America.
Daniel F ComiskeyFrom the Center for Childhood Cancer at the Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America; The Department of Pediatrics, and Molecular, Cellular and Developmental Biology (MCDB) program, The Ohio State University, Columbus, Ohio, United States of America; Center for RNA Biology, Wexner Medical Center, The Ohio State University, Columbus, Ohio, United States of America.
Matthew F RouhierFrom the Center for Childhood Cancer at the Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America.
Fuad MohammadFrom the Center for Childhood Cancer at the Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America; Center for RNA Biology, Wexner Medical Center, The Ohio State University, Columbus, Ohio, United States of America.
Thomas W BebeeFrom the Center for Childhood Cancer at the Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America; The Department of Pediatrics, and Molecular, Cellular and Developmental Biology (MCDB) program, The Ohio State University, Columbus, Ohio, United States of America.
Dawn S ChandlerFrom the Center for Childhood Cancer at the Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America; The Department of Pediatrics, and Molecular, Cellular and Developmental Biology (MCDB) program, The Ohio State University, Columbus, Ohio, United States of America; Center for RNA Biology, Wexner Medical Center, The Ohio State University, Columbus, Ohio, United States of America.
Nationwide Children's Hospital · USThe Ohio State University · USThe Ohio State University Wexner Medical Center · US

Funding

Coordinately regulated alternative splicing in DNA damage and cancerR01CA133571 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI CHANDLER, DAWN S · 2010 to 2014
$1.3M
NCI NIH HHS 1R01CA133571NCI NIH HHS R01 CA133571
6 · The paper itself

Abstract

MDM2 and MDMX are the chief negative regulators of the tumor-suppressor protein p53 and are essential for maintaining homeostasis within the cell. In response to genotoxic stress and also in several cancer types, MDM2 and MDMX are alternatively spliced. The splice variants MDM2-ALT1 and MDMX-ALT2 lack the p53-binding domain and are incapable of negatively regulating p53. However, they retain the RING domain that facilitates dimerization of the full-length MDM proteins. Concordantly, MDM2-ALT1 has been shown to lead to the stabilization of p53 through its interaction with and inactivation of full-length MDM2. The impact of MDM2-ALT1 expression on the p53 pathway and the nature of its interaction with MDMX remain unclear. Also, the role of the architecturally similar MDMX-ALT2 and its influence of the MDM2-MDMX-p53 axis are yet to be elucidated. We show here that MDM2-ALT1 is capable of binding full-length MDMX as well as full-length MDM2. Additionally, we demonstrate that MDMX-ALT2 is able to dimerize with both full-length MDMX and MDM2 and that the expression of MDM2-ALT1 and MDMX-ALT2 leads to the upregulation of p53 protein, and also of its downstream target p21. Moreover, MDM2-ALT1 expression causes cell cycle arrest in the G1 phase in a p53 and p21 dependent manner, which is consistent with the increased levels of p21. Finally we present evidence that MDM2-ALT1 and MDMX-ALT2 expression can activate subtly distinct subsets of p53-transcriptional targets implying that these splice variants can modulate the p53 tumor suppressor pathway in unique ways. In summary, our study shows that the stress-inducible alternative splice forms MDM2-ALT1 and MDMX-ALT2 are important modifiers of the p53 pathway and present a potential mechanism to tailor the p53-mediated cellular stress response.

Indexed as

Signal TransductionAlternative SplicingCell Cycle CheckpointsCell Line, TumorDNA DamageHumansNeoplasmsProtein Interaction MapsProtein IsoformsProtein MultimerizationProto-Oncogene Proteins c-mdm2Transcriptional ActivationTumor Suppressor Protein p53Protein IsoformsProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53

Identifiers

PMID25105592
PMCPMC4126728
OpenAlexW2094837086

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.